The key to successful cancer immunotherapy is to induce an effective anticancer immunity that will overcome the acquired cancer-specific immune tolerance. In this study, we found that dendritic cells (DCs) from multiple myeloma (MM) patients suppressed rather than induced a cancer cell-specific immune response. We demonstrated that CD4 + CD25 high T cells from MM patients suppressed the proliferation of activated peripheral blood lymphocytes. Further analysis illustrated that MM cell lysates or MM-specific idiotype immunoglobulins (MM Id-Ig) specifically induced the expansion of peripheral CD4 + CD25 high
FoxP3
high T regulatory (Treg) cells in vitro. Supraphysiological expression of calnexin (CNX) using lentiviral (LV) vectors in DCs of MM patients overcame the immune suppression and enhanced MM-specific CD4 and CD8 T-cell responses. However, overexpression of CNX did not affect the peripheral expansion of Treg cells stimulated by MM antigens. Thus, the immune suppression effect of Treg cells in cancer patients may be overcome by improving antigen processing in DCs, which in turn may lower the activation threshold of the immune effector cells. This concept of modulating anticancer immunity by genetically engineering cancer patients' DCs may improve immunotherapeutic regimens in cancer treatment.
introduction
Multiple myeloma (MM), an incurable B-cell neoplasm, accounts for ~1% of all cancers but it is the second most common hematologic malignancy after lymphoma. The standard high-dose chemotherapy and autologous transplant used in MM treatment only offer limited control of the disease.
1,2 A potentially effective strategy for curing MM is allogeneic stem cell transplant. However, allogeneic stem cell transplant is associated with high treatmentrelated mortality and limited to individuals with HLA-matched donors. Furthermore, myeloma cells may escape from the graft versus myeloma effect in a large number of patients undergoing this treatment. Consequently, most patients eventually die from recurrent disease. [3] [4] [5] Further studies are urgently needed to overcome these obstacles and lead to successful and effective immunotherapy for myeloma.
Immunotherapy is considered an alternative means for treating MM and has been the focus of multiple studies. [6] [7] [8] Dendritic cells (DCs) are a key player in establishing an effective anticancer immunity. 9, 10 The DC immunization approach for cancer therapy has gained limited success mainly because many patients have established strong immune tolerance toward their cancer cells. Much research is now focused on breaking the tolerance established in cancer patients. 7, 11 Recent evidence suggests that DCs in cancer patients are tolerized early in their development. [11] [12] [13] Therefore, it may be difficult to alter the functions of DCs or their precursors by means of extracellular adjuvants such as cytokines and inflammatory mediators. 14 However, DCs or their precursors may be genetically engineered to alter their T-cell stimulatory functions and re-direct immune reactivity. We have previously reported that DCs, modified by means of lentiviral (LV) vectors to express exogenous cytokines, costimulatory molecules or small interfering RNAs, can enhance T-cell responses. 15 Others have shown that chaperones in the cytosol such as heat-shock proteins, calreticulin, gp96, tapsin, ER60 and calnexin (CNX) could enhance antigen-specific cellular immunity. [16] [17] [18] Overexpression of CNX in DCs upregulates class I major histocompatibility complex (MHC-I) and promotes central memory T-cell response (L.-J. Chang and B. Wang, unpublished results). Thus, the activation of specific anticancer immunity using genetically modified DCs from cancer patients is a promising new immunotherapeutic modality but has not yet been clinically tested.
A growing body of evidence now indicates that cancer cells promote T regulatory (Treg) cell trafficking, differentiation, and expansion, and the Treg cells may suppress the activities of cancer-specific T cells and natural killer cells. [19] [20] [21] [22] [23] In MM patients, the number of CD4 + , CD25 high hand, the Treg cells in MM have been reported to be dysfunctional and unable to suppress anti-CD3 activated T-cell proliferation. 25 The specific MM antigens that mediate the Treg cell increase have not been characterized. It is also still controversial whether the Treg cells are immunosuppressive, and whether the expansion of the Treg cells is a central or peripheral lymphoid event in MM patients. 26, 27 In this report, we analyzed CD4 + CD25 + Treg and DC functions in MM patients and provided evidence that CD4 + CD25 + Treg had immunosuppressive capacity and that both MM cell lysates and MM-specific idiotype immunoglobulin (MM Id-Ig) loaded DCs triggered a suppressive antimyeloma immune response exemplified by the expansion of peripheral Treg cells. These tolerizing DC functions, however, could be overcome by LV-mediated expression of the CNX gene in the patient's DCs, which, in turn, lead to an anti-MM response by the effector T cells. We believe that this is the first study to report that engineered DCs from MM patients can overcome peripheral Treg cell-induced immune tolerance.
results dc phenotype analysis in healthy donors and MM patients
For immune analysis, we pulsed MM patients' monocyte-derived DCs with MM cell lysates and cocultured them with autologous non-adherent peripheral blood mononuclear cells (PBMCs) as illustrated in Figure 1a . The MM cells were highly enriched (96-98%) as shown by using antibody (Ab)-conjugated magnetic beads specific to MM phenotype: CD38 + CD138 + CD56 + CD45 - (Figure 1b) . To investigate whether DCs from MM patients were immunologically different, the phenotypes of mature DCs from five healthy donors (HDs) and five MM patients (MM) were compared. Figure 1c illustrates the results from CD11c + DC phenotypes from HD and MM patients. Although minor variations existed, there was no significant difference in the surface phenotype between these two groups. CD1a  CD86  CD40  CD83  CD14  HLA-I  CD80   91  76  84  49  28  0  94  52   76  76  57  31  18  1  86  52   99  77  92  76  18  0  95  57   96  62  68  62  24  2  90  68   98  82  85  67  45  0  96  77   82  84  73  36  54  0  88  62   1  0  1  1  3  0  1 It is known that during cancer progression, patients may develop strong Treg activities. We examined Treg-related CD4 + CD25 high lymphocytes in the peripheral blood of MM patients and HD. MM patients showed elevated levels of CD4 + CD25 high lymphocytes (mean 11.51 ± 1.716%) in the peripheral blood than did HD (mean 6.57 ± 1.082%; P = 0.03, To express myeloma-specific Id-Ig, we cloned the MM κ cDNA into an LV vector (pTYF-EF) under the control of a strong elongation factor 1α promoter. The cDNA was fused with an N-terminal Flag tag (pTYF-EF-κ-flag), and the expression confirmed by Western analysis using an anti-Flag Ab (Figure 4c , with an internal expression control of α-tubulin). Efficient transduction of DCs with LV vectors is illustrated in Figure 4d ; up to 40% of DCs were transduced with a reporter LV-eGFP at a multiplicity of infection of 10. 
MM id-ig displays low immunogenicity but induces a specific treg-cell response
To assess the immunogenicity of the MM Id-Ig, we transduced autologous immature DCs with the MM Id-Ig LV-κ vector (DC-LV-κ) or a control LV-LacZ vector (DC-LV-LacZ). As positive control, immature DCs were pulsed with memory antigen tetanus toxoid (TT) for 4 hours before maturation (DC/TT). The DCs were cocultured with autologous T cells for 14 days and immune effector function was examined. Background response to the nontransduced DCs was subtracted. For HD there was no difference between DC-LV-κ and DC-LV-lacZ in the CD4 and CD8 T-cell response (Figure 5a ). In contrast, DC-LV-κ induced less CD4 and CD8 T-cell response than did DC-LV-LacZ as illustrated by intracellular analysis of TNF-α and IFN-γ (Figure 5a ). Further analysis of CD4 + CD25 + and FoxP3 Treg cells showed that DC-LV-κ, but not DC-LV-LacZ or DC/TT, markedly upregulated FoxP3 expression in CD4 + CD25 high T cells in the corresponding MM patients (mean fluorescence index of 16.85 for DC-LV-κ, versus 8.23 and 8.21 for DC-LV-LacZ and DC/TT, respectively, P < 0.001). By contrast, no significant difference was found for HD (Figure 5b and c) .
It has been reported that CD4 + CD25 + Treg cells of MM patients are dysfunctional. 27 We evaluated CD4 + CD25 + versus CD4 + CD25 − T cells of MM patients and HD in a PBMC proliferation assay. Autologous CD4 + CD25 + or CD4 + CD25 − T cells were cocultured with 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled PBMCs at different ratios and activated with phytohemagglutinin. The intensity of CFSE in the culture decreases with increased cell proliferation. The results showed that CD4 + CD25 + T cells from MM patients suppressed PBMC proliferation in a dose-dependent manner (Figure 5d and e) , similar to that of HD (not shown). The control CD4 + CD25 − T cells, by contrast, did not show such an effect.
lV-cnX-transduced dcs enhance the MM-specific cd4 and cd8 t-cell response Both MM cell lysates and the specific Id-Ig antigens failed to induce an immune effector response but instead, promoted a strong Treg-cell response. To overcome this MM-specific immune suppression, we attempted to modify the antigen presentation functions of MM patients' DCs. CNX is a chaperone in the endoplasmic reticulum critical to the processing of glycoproteins and has been shown to promote antigen presentation in immune cells. 28, 29 We explored the effect of CNX on MM patients' DCs and T cells by LV-mediated overexpression of CNX in patients' DCs. The human CNX cDNA was cloned into LV vector (LV-CNX) behind a strong elongation factor 1α promoter. Western analysis detected high expression of CNX in CEM-NKR cells (a CNX-defective cell line) after LV-CNX transduction (Figure 6a) . Upregulation of CNX expression was also confirmed in DCs when transduced with LV-CNX (not shown).
To assess the effect of CNX, immature DCs from MM patients were transduced with LV-CNX (DC-LV-CNX/MM), and control DCs were transduced with LV-LacZ (DC-LV-LacZ/MM), and then pulsed with MM lysates. After maturation, the DCs were cocultured with autologous PBMCs at a ratio of 1:20 for 14 days. The IFN-γ and TNF-α response of the T cells was analyzed upon re-stimulation 
lV-cnX enhances the MM id-ig-specific dc immunity
The above study demonstrates that DCs from MM patients, when transduced with LV-CNX can effectively upregulate MMspecific CD4 and CD8 T-cell responses. We have observed an enhanced immune activation effect of CNX in a separated study (Supplementary Figure S3) . T cells were rapidly expanded within 3 days when LV-CNX-DCs were included in the coculture (Figure 7a , clusters of expanded cells). This was verified by CFSE proliferation analysis. We pre-stained the T cells with CFSE before DC coculture. After 3 days, the CFSE intensity of the LV-CNX DC coculture group markedly decreased as compared with that of the other three groups, indicating an increased T-cell proliferation induced by LV-CNX (Figure 7a , right panel).
To investigate whether CNX could overcome the tolerance effect of MM-specific antigens, the MM Id-Ig gene (LV-κ) was transduced into autologous immature DCs; also included were LV-CNX (DC-LV-κ + LV-CNX), and LV-LacZ alone as control (DC-LV-LacZ). The mature DCs were cocultured with autologous non-adherent PBMCs, and antigen-specific T-cell response was examined by ICCS for IFN-γ and TNF-α. The result showed an enhanced response of CD4 and CD8 effector T cells when DCs were co-transduced with LV-CNX (Figure 7b) . The number of CD4 + CD25 high
FoxP3
high Treg cells between the DC-LV-κ + LV-CNX and the DC-LV-κ alone, however, was not significantly changed (not shown).
To directly correlate the immune effector function with anticancer immunity, we examined the cytotoxic activity of the MMspecific T cells, using a non-radioactive target cell killing assay. 
discussion
Immune tolerance to cancer antigens may arise from immune ignorance, deletion or functional inactivation (anergy) of cancerspecific T cells. 13, 30 A growing body of evidence now supports the notion that induction and expansion of regulatory T cells may be responsible for the lack of a clinically-sufficient anticancer immune response. 23 The latter has been verified in animal cancer models and in many studies where evidence of the expansion of CD4 + CD25 high FoxP3 + Treg cells has been reported in different malignancies, including that of MM. 24 Even though the immune system of cancer patients is constantly exposed to cancer antigens, these antigens often fail to deliver a "danger signal"; instead, they tend to establish tolerance. MM cells produce a number of immune modulators that may suppress the anticancer immune response, such as TGF-β, interleukin-10 (IL-10), vascular endothelial growth factor and mucin-1. 31 These factors could block DC differentiation and function, resulting in immature and/or partially differentiated DCs. 12 These dysfunctional DCs may process and present cancer antigens and stimu- 24 it is conceivable that this in vitro expansion of Treg cells is representative of the in vivo response.
Understanding how Treg cells expand in cancer patients will help address important cancer tolerance and therapy issues. T cells may develop from the thymus into naturally occurring or adaptive Treg cells. 33 The normal FoxP3-negative naïve T cells may differentiate into FoxP3-positive Treg cells upon low dose or systemic antigen stimulation in the presence of TGF-β. Cancer antigen-specific CD4 + CD25 + Treg cells have been isolated from tumor-infiltrating lymphocytes and shown to suppress the function of CD4 T-effector cells. 34 In a transgenic autoimmune disease mouse model of multiple sclerosis, it was found that myelin basic protein-specific Treg cells, compared to Treg cells specific for other antigens, are superior in disease protection. 35 Cancer-specific Treg expansion has been reported in different mouse cancer models. 34, 36 Treg cells may interact with antigen-specific effector cells and antigen presenting cells and it is likely that multiple immune suppression mechanisms are operative. Control of Treg-cell expansion may facilitate the development of anticancer immunity. For example, selective elimination of CD4 + CD25 + Treg cells using IL-2-diphtheria toxin conjugate in renal cell carcinoma cancer patients has been shown to enhance vaccine-mediated anticancer immunity. 37 We have demonstrated that the MM immune tolerance can be overcome by modifying DCs to express CNX, an accessory protein that enhances antigen processing and promotes DC and T-cell interactions. Overexpression of CNX may modulate the activation threshold of cancer-specific effector T cells. CNX plays a key role in both major histocompatibility complex-class I and II antigen processing pathways and may also be involved in CD1d lipid antigen presentation.
28,38 CNX may also enhance cross-presentation of exogenous antigens through the class I major histocompatibility complex pathway. 39 MM patients' DCs presenting cancer antigens do not induce an effective T helper or cytotoxic T-lymphocyte response against cancer cells. LV-CNX-modified MM DCs, by contrast, effectively boosted cytokine production in both CD4 and CD8 T cells coupled with increased cancer cell killing activity. In a separate study, we have observed that DCs modified with LV-CNX can induce effector T-cell activation exhibiting increased T-cell receptor affinity and reduced antigenic threshold, and that the activated T cells display a central memory phenotype (B. Wang, S. Han, and L.-J. Chang, manuscript in preparation). These findings indicate that the tolerogenic DCs in cancer patients may be engineered into reactive DCs to promote anticancer immunity with potential clinical benefit. Although our results suggest that DCs modified with CNX do not alter the activation potential of the FoxP3 + Treg cells specific to cancer antigens, one cannot rule out the possibility that the activated Treg cells may have altered functions. In summary, cancer patients including MM patients gradually develop tolerance to their cancer cells with increased Treg activities. We have shown that this tilted balance of cancer immunity may be altered by properly engineering DCs using LV-CNX. Combining this approach of using a modified DC vaccine with other ways to modulate the number and/or the functions of Treg may become an effective anticancer immunotherapy approach. The results of our study support the potential application of CNX-based immunotherapy in MM and possibly other malignancies.
MAteriAls And Methods
Patients and donors. Bone marrow and peripheral blood were obtained from patients with newly diagnosed or relapsed/refractory MM who signed informed consent approved by the Institutional Review Board at the University of Florida. Peripheral blood of anonymous HDs was obtained from LifeSouth Blood Center, Gainesville, FL.
Generation of monocyte-derived DCs and bone marrow-derived stromal cells. PBMC from HDs or patients with MM were isolated from buffy coats by gradient density centrifugation in Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO) as previously described. 15 DCs were prepared according to the method of Thurner et al., 40 with the following modifications: on Day 0, the PBMCs were incubated at 37 °C for 2 hours and the adherent monocytic cells were cultured in AIM-V medium (Invitrogen, San Diego, CA). On day 1, one half of the AIM-V medium was supplemented with 50 ng/ml of recombinant human granulocyte-macrophage colony-stimulating factor and 25 ng/ml of IL-4 (Biosource International, Camarillo, CA). On day 3, fresh AIM-V medium containing 100 ng/ml of granulocyte-macrophage colony-stimulating factor and 50 ng/ml of IL-4 was added to the culture. On day 5, the non-adherent cells were harvested by gentle pipetting. The purity of immature DCs was routinely examined using fluorochrome-conjugated anti-CD11c Ab (BD Pharmingen, San Diego, CA). Immature DCs were induced into maturation with TNF-α (20 U/ml, Biosource International) and lipopolysaccharide (1 µg/ml, Sigma-Aldrich). The phenotype of the mature DCs was verified with fluorochrome-conjugated antibodies against different DC maturation markers including CD1a, CD83, CD80, CD86, CD40 (BD Pharmingen), HLA-I (HLA-ABC) and HLA-DR (Caltag, Invitrogen, San Diego, CA). These DCs are functional in stimulating an antigen-specific T-cell response as illustrated in Supplementary Figure S1 and Supplementary Figure S5 .
BM-derived stromal cells were generated by plating BM cells in α-minimum essential medium, supplemented with penicillin and streptomycin and 20% fetal bovine serum, and the attached cells were propagated as stromal cell culture.
Isolation of MM cells and preparation and pulsing of cell lysates. MM cells were enriched from bone marrow mononuclear cells by negative selection with magnetic beads according to the manufacturer's instructions (Stem Cell Technologies, Vancouver, BC) or enriched by FACS with the following mixture of antibodies: fluorescein isothiocyanate-labeled antihuman CD38, phycoerythrin (PE)-labeled antihuman CD138, PE-Cy7 labeled anti-CD56 and allophycocyanin-labeled anti-CD45 monoclonal Ab (BD Pharmingen, San Diego, CA). These cells and the Epstein-Barr virus-transformed B-cell lines from different donors were lysed by means of five rounds of freeze-and-thaw carried out between liquid nitrogen and a 37 °C water bath. Cell debris was discarded by centrifugation (20,800g, 2 minutes) and the supernatants were stored frozen at -80 °C until use. The cell lysates were used to pulse immature DCs at a ratio of 1:1 (cell number) for 4 hours. TT (inactivated tetanus toxin) was used to pulse the DCs at a concentration of 50 U/ml for 4 hours. Subsequently, DCs were matured with lipopolysaccharide (1 µg/ml) and TNF-α (20 U/ml) for 24 hours.
Isolation and expression of MM Id-Ig gene. The V H and V L genes of FACS-sorted MM cells were polymerase chain reaction-amplified using primers specific for H chain and L chain, followed by cloning and sequencing. The reverse primers of H chain and L chain were complementary to the constant (C) region. The forward primers for H chain and L chain were complementary to the V-region of different subfamilies. The sequences of these primers are listed in Table 1. LV vector preparation and transduction of DCs. LVs were constructed as described previously. [41] [42] [43] The self-inactivating pTYF vectors expressing CNX, MM κ chain, a κ-Flag fusion, nLacZ and enhanced green fluorescent protein genes were under the elongation factor 1α promoter control. The day 5 immature DCs, plated at 5 × 10 5 per well in a 24-well plate containing 200 µl of medium supplemented with granulocyte-macrophage colonystimulating factor (50 ng/ml) and IL-4 (25 ng/ml), were transduced with concentrated LVs at a multiplicity of infection of 40. The infected cells were incubated at 37 °C for 2 hours with gentle shaking every 30 minutes, followed by adding 1 ml of medium and incubated for an additional 12 hours. DC maturation was induced by adding lipopolysaccharide (1 µg/ml) and TNF-α (20 µ/ml) and incubated for 24 hours.
FACS sort of CD4 + CD25 + lymphocyte subsets. CD4 + CD25 + peripheral blood lymphocytes of HDs and MM patients were isolated with a FACSAria high-speed cell sorter (BD Bioscience). Briefly, PBMC were incubated with PE-anti-human CD25 Ab (BD Pharmingen) and allophycocyaninanti-human CD4 Ab (Caltag) for 30 minutes on ice in the dark. The cells were washed three times before sorting. Lymphocytes were gated based on forward and side scatter for further analysis of CD4 and CD25 expression. CD4 + CD25 + and CD4 + CD25 -T-cell populations were sorted according to fluorescence of PE (CD25) and allophycocyanin (CD4). The mean purity of the sorted CD4 + CD25 + and CD4 + CD25 − cells was in the range of 98%. CFSE labeling-based lymphocyte proliferation assay. PBMC were suspended in phosphate-buffered saline containing 0.1% bovine serum albumin at 2 × 10 6 /ml and incubated with CFSE (Molecular Probes, Eugene, OR) at a final concentration of 1 µmol/l for 7 minutes at 37 °C. Cells were washed and resuspended in culture medium for 15 minutes to stabilize the CFSE staining. The CFSE labeled PBMC (responders) were cultured in a 96-well U-shape plate at 4 × 10 4 cells/well with phytohemagglutinin (PHA-P, 1 µg/ml, Sigma-Aldrich, St. Louis, MO) in the presence of varying amounts of CD4 + CD25 + T cells (Treg population) and CD4 + CD25 -T cells (control). After 3 days, cells were harvested and CFSE intensity of gated lymphocytes was analyzed by flow cytometry. The suppression effect of Treg was expressed as the relative decrease of CFSE low cells [100 × (1-% CFSE low PBMC in coculture/% total CFSE low PBMC)]. CFSE autofluorescence of unlabeled CD4 + CD25 + and CD4 + CD25 − T cells was subtracted using CellQuest software to exclude background interference with CFSE low cells.
DC and non-adherent PBMC coculture. Non-adherent PBMC were cocultured with autologous mature DCs at a ratio of 20:1 in serum-free AIM-V medium for 3 days. On day 3, IL-7 (10 ng/ml) and IL-2 (12.5 U/ml) were added and fresh medium replenished every other day for 14 days. On day 13, the T cells were collected for Treg cell analysis using fluorochromeconjugated Abs against CD4, CD25, and FoxP3. On day 14, the T cells were re-stimulated with the same antigen treated mature DCs. For myeloma cell lysate-pulsed DCs, the T cells were re-stimulated with phorbol myristate acetate (10 ng/ml or 0.0162 µmol/l) and ionomycin (1 µg/ml, Sigma-Aldrich) for 4 hours, with Brefeldin A (1.5 µg/ml) added during the last 2.5 hours of culture. Then, the cells were fixed, permeablized, and stained with fluorescein isothiocyanate-labeled anti-IFN-γ-, PE-labeled anti-CD8, PE-Cy7-labeled anti-CD4 and allophycocyanin-labeled anti-TNF-α monoclonal Abs (BD Pharmingen). The cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences).
Immune cell cytotoxicity assay. The immune cell cytotoxicity assay was based on a non-radioactive fluorometric analysis of T-lymphocyte antigen-specific lysis assay as described by Sheehy et al., 44 with modifications. 9 On day 14 after DC:T cell coculture, the T cells were re-stimulated and 5 days later, harvested as effector cells. The target cells included stromal cells infected with LV-κ or LV-lacZ, autologous MM cells or EpsteinBarr virus-transformed B-cell line (BLCL). The target cells were labeled with PKH-26 (Sigma-Aldrich) and CFSE (Molecular Probes). The double-labeled target cells were dispensed in duplicate at 1 × 10 4 cells/well into 96-well U-bottom plates (BD Biosciences). Effector cells were added at various effector:target (E:T) ratios. After 5 hours of incubation, the cells were harvested and fixed in 1% paraformaldehyde in phosphatebuffered saline and analyzed using a FACSCalibur flow cytometer and the CellQuest program (BD). PKH-26 positive cells were gated and the same cell numbers were acquired for each sample. The percentage of target cell lysis was determined by the disappearance of the antigen-specific targets from the CFSE high population compared to the control targets in the CFSE high population.
Western analysis. Cell extracts were prepared in lysis buffer of Cell Signaling Technology (Danvers, MA) containing proteinase inhibitors (Sigma-Aldrich). The protein samples were separated on sodium dodecyl sulfate 4-12% gradient polyacrylamide gels, electro-blotted to polyvinylidene difluoride membranes (PerkinElmer, Boston, MA), and exposed to antibodies against Flag or CNX (Santa Cruz Biotechnology, Santa Cruz, CA). The signals were detected using a horseradish peroxidase kit with enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Statistics. Data were analyzed using GraphPad Prism 4 analysis software (GraphPad Software, San Diego, CA) and student's t-test. A 2-sided P value of <0.05 was considered statistically significant.
suPPleMentAry MAteriAl Figure S4 . Phenotype comparisons of DCs pulsed with cell lysates from different sources. Figure S2 . Proportions of CD4 + and CD8 + cells in PBMCs of MM (multiple myeloma) patients (MM1 and MM2) and a healthy donor (HD). Figure S3 . Calnexin (CNX) alone does not non-specifically upregulate effector cell functions, but supraphysiological expression of CNX in DCs promotes T cell response against known tumor antigens (HPV E6 and E7). Figure S1 . Development of antigen-specific T cell response in vitro. Figure S5 . Analyses of cytokine-producing CD4 and CD8 T cells stimulated by allogeneic mature DCs or monocytes.
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